Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, food, animal healthcare, biotech, crop protection, and specialty chemicals and biocides companies. More Details
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has Hikal's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HIKAL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: HIKAL underperformed the Indian Pharmaceuticals industry which returned 44.2% over the past year.
Return vs Market: HIKAL exceeded the Indian Market which returned 0.2% over the past year.
Price Volatility Vs. Market
How volatile is Hikal's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's What Hikal Limited's (NSE:HIKAL) Shareholder Ownership Structure Looks Like
1 month ago | Simply Wall StHikal (NSE:HIKAL) Shareholders Have Enjoyed An Impressive 162% Share Price Gain
1 month ago | Simply Wall StHikal Limited (NSE:HIKAL) Passed Our Checks, And It's About To Pay A ₹0.20 Dividend
Is Hikal undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HIKAL (₹168.95) is trading below our estimate of fair value (₹242.87)
Significantly Below Fair Value: HIKAL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HIKAL is poor value based on its PE Ratio (27.5x) compared to the IN Pharmaceuticals industry average (22.6x).
PE vs Market: HIKAL is poor value based on its PE Ratio (27.5x) compared to the Indian market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: HIKAL is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: HIKAL is overvalued based on its PB Ratio (2.5x) compared to the IN Pharmaceuticals industry average (2.2x).
How is Hikal forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HIKAL's forecast earnings growth (34% per year) is above the savings rate (7.2%).
Earnings vs Market: HIKAL's earnings (34% per year) are forecast to grow faster than the Indian market (25.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HIKAL's revenue (13.9% per year) is forecast to grow faster than the Indian market (11.3% per year).
High Growth Revenue: HIKAL's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HIKAL's Return on Equity is forecast to be high in 3 years time
How has Hikal performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HIKAL has high quality earnings.
Growing Profit Margin: HIKAL's current net profit margins (5.1%) are lower than last year (6.7%).
Past Earnings Growth Analysis
Earnings Trend: HIKAL's earnings have grown by 12.3% per year over the past 5 years.
Accelerating Growth: HIKAL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HIKAL had negative earnings growth (-33.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).
Return on Equity
High ROE: HIKAL's Return on Equity (9.1%) is considered low.
How is Hikal's financial position?
Financial Position Analysis
Short Term Liabilities: HIKAL's short term assets (₹7.7B) exceed its short term liabilities (₹6.0B).
Long Term Liabilities: HIKAL's short term assets (₹7.7B) exceed its long term liabilities (₹3.6B).
Debt to Equity History and Analysis
Debt Level: HIKAL's debt to equity ratio (68.7%) is considered high.
Reducing Debt: HIKAL's debt to equity ratio has reduced from 99.1% to 68.7% over the past 5 years.
Debt Coverage: HIKAL's debt is well covered by operating cash flow (50.8%).
Interest Coverage: HIKAL's interest payments on its debt are well covered by EBIT (3.4x coverage).
What is Hikal current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HIKAL's dividend (0.72%) is higher than the bottom 25% of dividend payers in the Indian market (0.55%).
High Dividend: HIKAL's dividend (0.72%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).
Stability and Growth of Payments
Stable Dividend: HIKAL's dividend payments have been volatile in the past 10 years.
Growing Dividend: HIKAL's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (19.9%), HIKAL's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Sameer Hiremath (46 yo)
Mr. Sameer Hiremath has been Joint Managing Director of Hikal Limited since November 10, 2011 and serves as its Chief Executive Officer. Mr. Hiremath served as President of Hikal Limited since November 10, ...
CEO Compensation Analysis
Compensation vs Market: Sameer's total compensation ($USD475.21K) is above average for companies of similar size in the Indian market ($USD315.14K).
Compensation vs Earnings: Sameer's compensation has been consistent with company performance over the past year.
|Joint MD||8.92yrs||₹35.00m||0.47% |
|Non-Executive Director||8.67yrs||₹1.02m||no data|
|Member of Scientific Advisory Board||no data||₹300.00k||no data|
|Founder||no data||₹48.99m||1.09% |
|Independent Non-Executive Director||26.33yrs||₹2.12m||0.012% |
|Independent Non-Executive Director||no data||₹2.02m||0.016% |
|Independent Non-Executive Director||24.17yrs||₹1.72m||0.037% |
|Non-Executive Director||no data||₹1.82m||7.84% |
|Member of Scientific Advisory Board||no data||no data||no data|
|Non-Executive Director||no data||₹1.12m||0.018% |
|Independent Director||2.67yrs||₹1.32m||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: HIKAL's board of directors are seasoned and experienced ( 16.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hikal Limited's company bio, employee growth, exchange listings and data sources
- Name: Hikal Limited
- Ticker: HIKAL
- Exchange: NSEI
- Founded: 1988
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹20.838b
- Shares outstanding: 123.30m
- Website: https://www.hikal.com
Number of Employees
- Hikal Limited
- Great Eastern Chambers
- Sector 11
- Navi Mumbai
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|524735||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Aug 1998|
|HIKAL||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Aug 1998|
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, food, animal healthcare, biotech, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/28 12:45|
|End of Day Share Price||2020/10/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.